Hypothesis links cumulative levodopa exposure to frailty and reduced healthspan in Parkinson's disease

Levodopa remains the cornerstone of symptomatic treatment in Parkinson’s disease, providing substantial motor benefit and improved quality of life. While epidemiological studies have suggested improved survival in the modern levodopa era compared with the pre-levodopa era, these observations derive primarily from observational cohorts rather than randomized trials. Yet many patients experience severe functional decline after 5–10 years, a paradox that challenges the reputation of our most potent therapy. Similar divergences between early symptomatic benefit and adverse long-term outcomes have been observed in other areas of medicine. For example, positive inotropic agents such as milrinone improved short-term exercise tolerance in heart failure but were later associated with increased mortality in long-term trials. Antiarrhythmic agents encainide and flecainide effectively suppressed ventricular arrhythmias yet increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). In diabetes, intensive glucose lowering strategies improved metabolic control but increased cardiovascular mortality in the ACCORD trial, and earlier studies of tolbutamide in the University Group Diabetes Program (UGDP) also suggested excess cardiovascular deaths despite improved glycemic control. These examples illustrate how therapies with clear short-term physiological benefits may reveal unanticipated risks when evaluated over longer time horizons. Similarly, the long-term use of levodopa may introduce a cumulative burden of complications that may independently accelerate decline. We propose the conceptual framework of levodopa-accelerated frailty as a testable hypothesis to explore this possibility. This framework synthesizes evidence across seven pathways that may interact or overlap in contributing to frailty: dyskinesia, psychosis, orthostatic hypotension, weight loss, impulse control disorders, sleep disturbances, and elevated homocysteine. Each complication has been associated with increased risks of dementia, hospitalization, falls, or mortality in observational studies, with reported hazard ratios generally ranging from approximately 1.5 to over 6. Together, they form a synergistic web of decline that may transform a highly effective symptomatic therapy into a contributor to late-stage vulnerability. This hypothesis reframes a potential therapeutic paradox: a treatment that improves early symptomatic outcomes may also interact with mechanisms that contribute to frailty later in the disease course. The clinical implication is not levodopa phobia, but a healthspan-preservation strategy focused on minimizing cumulative iatrogenic burden. This involves adhering to the lowest effective dose, continuous reassessment, and integration with exercise, nutrition, and adjunctive therapies. Recognizing this potential pattern of levodopa-accelerated frailty may help reconcile the discrepancy between early symptomatic success and the later emergence of vulnerability. We emphasize that this model is a hypothesis and call for long-term, prospective studies to test whether cumulative levodopa exposure contributes to frailty and reduced healthspan.